A Scoping Review of Preclinical Paradigms for Clinically Tested Medications in Alcohol Use Disorder.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	A Scoping Review of Preclinical Paradigms for Clinically Tested Medications in Alcohol Use Disorder.
Συγγραφείς:	Nieto SJ; Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA.; Department of Psychology, University of California at Los Angeles, Los Angeles, California, USA., Donato S; Department of Psychology, University of California at Los Angeles, Los Angeles, California, USA., Baskerville WA; Department of Psychology, University of California at Los Angeles, Los Angeles, California, USA., McManus KR; Department of Psychology, University of California at Los Angeles, Los Angeles, California, USA., Lopez MF; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA., Becker HC; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA., Ray LA; Department of Psychology, University of California at Los Angeles, Los Angeles, California, USA.; Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, California, USA.
Πηγή:	Alcohol, clinical & experimental research [Alcohol Clin Exp Res (Hoboken)] 2026 May; Vol. 50 (5), pp. e70287.
Τύπος έκδοσης:	Journal Article; Scoping Review; Review
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Wiley Periodicals Country of Publication: United States NLM ID: 9918609780906676 Publication Model: Print Cited Medium: Internet ISSN: 2993-7175 (Electronic) Linking ISSN: 29937175 NLM ISO Abbreviation: Alcohol Clin Exp Res (Hoboken) Subsets: MEDLINE
Imprint Name(s):	Original Publication: Hoboken, NJ : Wiley Periodicals, [2023]-
Ιατρικοί όροι (MeSH):	Alcoholism/drug therapy , Alcoholism/psychology , Alcohol Deterrents*/therapeutic use, Drug Evaluation, Preclinical/methods ; Conditioning, Operant/drug effects ; Alcohol Drinking/drug therapy ; Alcohol Drinking/psychology ; Animals ; Humans ; Female ; Male ; Disease Models, Animal ; Rats
Περίληψη:	Despite increasing attention to the neurobiology of alcohol use disorder (AUD), development of effective pharmacotherapies remains limited. Many medications with promising preclinical profiles fail to translate into clinical efficacy. This scoping review characterizes preclinical studies evaluating medications for AUD that have also been tested in human laboratory paradigms or clinical trials. We focus on two widely used paradigms: the two-bottle choice (2BC) task, which measures alcohol consumption and preference, and operant reinstatement models, which capture relapse-like behavior. A systematic search and data extraction identified preclinical studies using 2BC and reinstatement paradigms to evaluate medications that progressed to human testing. Study characteristics (species, strain, sex, outcomes, and sample sizes) were recorded and effect sizes (corrected Cohen's d) were summarized across outcome domains. Ninety-two unique studies met criteria: 74 employing the 2BC paradigm and 18 using operant reinstatement models, including 1731 animals. Rats were the most common species and sex bias was pronounced: 77 2BC studies using only males, five only females, and all 18 reinstatement studies used male rats exclusively. For 2BC consumption, the largest effects were observed for medications with limited studies, such as levetiracetam (d = -4.58), while more extensively tested medications showed moderate effects, including prazosin (d = -0.74) and naltrexone (d = -0.63). For 2BC preference, levetiracetam again showed a large effect in a single study (d = -4.29). In reinstatement models, rimonabant showed the largest effect (d = -3.11), while naltrexone (d = -0.70), baclofen (d = -1.05), and varenicline (d = -0.72) had moderate effects. This review highlights substantial heterogeneity in study design and underutilization of reinstatement and female animals. Medications with moderate, replicable preclinical effects, especially those tested across both 2BC and reinstatement models, may hold greater translational promise. These findings offer key opportunities for enhancing the translational alignment of preclinical AUD pharmacotherapy research. (© 2026 Research Society on Alcohol.)
References:	Becker, J. B., and G. F. Koob. 2016. “Sex Differences in Animal Models: Focus on Addiction.” Pharmacological Reviews 68, no. 2: 242–263. https://doi.org/10.1124/pr.115.011163. Bell, R. L., S. R. Hauser, T. Liang, Y. Sari, A. Maldonado‐Devincci, and Z. A. Rodd. 2017. “Rat Animal Models for Screening Medications to Treat Alcohol Use Disorders.” Neuropharmacology 122: 201–243. https://doi.org/10.1016/j.neuropharm.2017.02.004. Burnette, E. M., S. J. Nieto, E. N. Grodin, et al. 2022. “Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.” Drugs 82, no. 3: 251–274. https://doi.org/10.1007/s40265‐021‐01670‐3. Carnicella, S., D. Ron, and S. Barak. 2014. “Intermittent Ethanol Access Schedule in Rats as a Preclinical Model of Alcohol Abuse.” Alcohol 48, no. 3: 243–252. https://doi.org/10.1016/j.alcohol.2014.01.006. Crabbe, J. C. 2014. “Use of Animal Models of Alcohol‐Related Behavior.” In Handbook of Clinical Neurology, vol. 125, 71–86. Elsevier. https://doi.org/10.1016/b978‐0‐444‐62619‐6.00005‐7. Crabbe, J. C., R. A. Harris, and G. F. Koob. 2011. “Preclinical Studies of Alcohol Binge Drinking.” Annals of the New York Academy of Sciences 1216: 24–40. https://doi.org/10.1111/j.1749‐6632.2010.05895.x. Crabbe, J. C., T. J. Phillips, R. A. Harris, M. A. Arends, and G. F. Koob. 2006. “REVIEW: Alcohol‐Related Genes: Contributions From Studies With Genetically Engineered Mice.” Addiction Biology 11, no. 3–4: 195–269. https://doi.org/10.1111/j.1369‐1600.2006.00038.x. DerSimonian, R., and N. Laird. 1986. “Meta‐Analysis in Clinical Trials.” Controlled Clinical Trials 7, no. 3: 177–188. https://doi.org/10.1016/0197‐2456(86)90046‐2. Donato, S., L. R. Meredith, S. J. Nieto, S. Bujarski, and L. A. Ray. 2024. “Medication Development for AUD: A Systematic Review of Clinical Trial Methodology.” Alcohol 120: 194–203. https://doi.org/10.1016/j.alcohol.2024.06.007. Hedges, L. V. 1981. “Distribution Theory for Glass's Estimator of Effect Size and Related Estimators.” Journal of Educational Statistics 6, no. 2: 107–128. Hyman, S. E. 2013. “Psychiatric Drug Development: Diagnosing a Crisis.” Cerebrum 2013: 5. Leeman, R. F., M. Heilig, C. L. Cunningham, D. N. Stephens, T. Duka, and S. S. O'Malley. 2010. “Ethanol Consumption: How Should We Measure It? Achieving Consilience Between Human and Animal Phenotypes.” Addiction Biology 15, no. 2: 109–124. https://doi.org/10.1111/j.1369‐1600.2009.00192.x. Leggio, L., and G. Colombo. 2025. “Preregistered Multi‐Site Preclinical Randomized Controlled Trials: The Beginning of a New Day in Reverse Translational Science?” Neuropsychopharmacology 50, no. 6: 873–874. https://doi.org/10.1038/s41386‐025‐02090‐7. Lguensat, A., A. Coppola, and E. Augier. 2023. “Animals Models Used to Study Alcohol Use Disorder.” In Alcohol and Alcohol‐Related Diseases, edited by S. Mueller and M. Heilig, 665–685. Springer International Publishing. https://doi.org/10.1007/978‐3‐031‐32483‐3_35. Litten, R. Z., M. Egli, M. Heilig, et al. 2012. “Medications Development to Treat Alcohol Dependence: A Vision for the Next Decade.” Addiction Biology 17, no. 3: 513–527. https://doi.org/10.1111/j.1369‐1600.2012.00454.x. Liu, X., and F. Weiss. 2002. “Additive Effect of Stress and Drug Cues on Reinstatement of Ethanol Seeking: Exacerbation by History of Dependence and Role of Concurrent Activation of Corticotropin‐Releasing Factor and Opioid Mechanisms.” Journal of Neuroscience 22, no. 18: 7856–7861. https://doi.org/10.1523/jneurosci.22‐18‐07856.2002. Meinhardt, M. W., I. Skorodumov, J. Jeanblanc, et al. 2025. “A New Module in the Drug Development Process: Preclinical Multi‐Center Randomized Controlled Trial of R‐Ketamine on Alcohol Relapse.” Neuropsychopharmacology 50, no. 6: 886–894. https://doi.org/10.1038/s41386‐025‐02071‐w. Munn, Z., E. Aromataris, C. Tufanaru, et al. 2019. “The Development of Software to Support Multiple Systematic Review Types: The Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI).” International Journal of Evidence‐Based Healthcare 17, no. 1: 36–43. Nieto, S. J., S. Donato, H. Du, et al. 2025. “Translating Medication Effects for Alcohol Use Disorder Across Preclinical, Human Laboratory, and Clinical Trial Outcomes Using Meta‐Analysis.” Translational Psychiatry 15, no. 1: 250. https://doi.org/10.1038/s41398‐025‐03473‐6. Nieto, S. J., H. Du, L. R. Meredith, S. Donato, M. Magill, and L. A. Ray. 2024. “Leveraging Meta‐Regression to Test if Medication Effects on Cue‐Induced Craving Are Associated With Clinical Efficacy.” Psychopharmacology 241, no. 8: 1679–1689. https://doi.org/10.1007/s00213‐024‐06589‐7. Nieto, S. J., E. N. Grodin, C. G. Aguirre, A. Izquierdo, and L. A. Ray. 2021. “Translational Opportunities in Animal and Human Models to Study Alcohol Use Disorder.” Translational Psychiatry 11, no. 1: 496. https://doi.org/10.1038/s41398‐021‐01615‐0. Ray, L. A., H. Du, R. Green, D. J. O. Roche, and S. Bujarski. 2021. “Do Behavioral Pharmacology Findings Predict Clinical Trial Outcomes? A Proof‐Of‐Concept in Medication Development for Alcohol Use Disorder.” Neuropsychopharmacology 46, no. 3: 519–527. https://doi.org/10.1038/s41386‐020‐00913‐3. Ray, L. A., L. R. Meredith, E. N. Grodin, et al. 2025. “A Neuroimmune Modulator for Alcohol Use Disorder: A Randomized Clinical Trial.” JAMA Network Open 8, no. 4: e257523. https://doi.org/10.1001/jamanetworkopen.2025.7523. Richter, C. P., and K. H. Campbell. 1940. “Alcohol Taste Thresholds and Concentrations of Solution Preferred by Rats.” Science 91: 507–509. https://doi.org/10.1126/science.91.2369.507. Roberts, A. J., C. J. Heyser, M. Cole, P. Griffin, and G. F. Koob. 2000. “Excessive Ethanol Drinking Following a History of Dependence: Animal Model of Allostasis.” Neuropsychopharmacology 22, no. 6: 581–594. https://doi.org/10.1016/S0893‐133X(99)00167‐0. Schacht, J. P., L. A. Ray, R. Miranda Jr., et al. 2024. “Effects of a Novel GABA‐B Positive Allosteric Modulator, ASP8062, on Alcohol Cue‐Elicited Craving and Naturalistic Alcohol Consumption in a Multisite Randomized, Double‐Blind, Placebo‐Controlled Trial.” Alcohol, Clinical and Experimental Research 48, no. 12: 2352–2363. https://doi.org/10.1111/acer.15468. Shaham, Y., U. Shalev, L. Lu, H. de Wit, and J. Stewart. 2003. “The Reinstatement Model of Drug Relapse: History, Methodology and Major Findings.” Psychopharmacology 168, no. 1–2: 3–20. https://doi.org/10.1007/s00213‐002‐1224‐x. Shalev, U., J. W. Grimm, and Y. Shaham. 2002. “Neurobiology of Relapse to Heroin and Cocaine Seeking: A Review.” Pharmacological Reviews 54, no. 1: 1–42. https://doi.org/10.1124/pr.54.1.1. Spanagel, R. 2017. “Animal Models of Addiction.” Dialogues in Clinical Neuroscience 19, no. 3: 247–258. https://pubmed.ncbi.nlm.nih.gov/29302222. The EndNote Team. 2013. EndNote. In (Version EndNote X9) [64 bit]. Clarivate. Viechtbauer, W. 2010. “Conducting Meta‐Analyses in R With the Metafor Package.” Journal of Statistical Software 36: 1–48. Weiss, F. 2011. “Alcohol Self‐Administration.” In Animal Models of Drug Addiction, edited by M. C. Olmstead, 133–166. Humana Press. https://doi.org/10.1007/978‐1‐60761‐934‐5_5. Yardley, M. M., and L. A. Ray. 2017. “Medications Development for the Treatment of Alcohol Use Disorder: Insights Into the Predictive Value of Animal and Human Laboratory Models.” Addiction Biology 22, no. 3: 581–615. https://doi.org/10.1111/adb.12349.
Grant Information:	K24AA025704 United States AA NIAAA NIH HHS; R21AA029771 United States AA NIAAA NIH HHS; F32AA029288 United States AA NIAAA NIH HHS; R01AA029701-01S1 United States AA NIAAA NIH HHS
Contributed Indexing:	Keywords: alcohol use disorder; pharmacotherapy; preclinical models; reinstatement; rodent studies; scoping review; translational research; two‐bottle choice
Substance Nomenclature:	0 (Alcohol Deterrents)
Entry Date(s):	Date Created: 20260508 Date Completed: 20260716 Latest Revision: 20260716
Update Code:	20260716
DOI:	10.1111/acer.70287
PMID:	42101829
Βάση Δεδομένων:	MEDLINE

Περιγραφή
ISSN:	2993-7175
DOI:	10.1111/acer.70287